Achillion Pharma (ACHN) Announces Presentation of ACH-4471 Data in Factor D Inhibition
- Futures flat as earnings season gathers pace
- Alibaba (BABA) Tops Q3 EPS by 17c, Revenues Rise 54%
- DuPont (DD) Tops Q4 EPS by 9c; Sees Merger Closing in First Half
- Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the Street
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced the presentation of two posters which detailed novel preclinical research into complement biology and the inhibition of factor D by ACH-4471 during the XXVIth International Complement Workshop, September 4 - 8, 2016, in Kanazawa, Ishikawa, Japan.
Researchers from Achillion presented a poster entitled “Assessment of complement-mediated bacterial killing and the effect of a small molecule factor D inhibitor in vitro” that described the effect of inhibiting different complement pathways on bacterial killing via two critical mechanisms: lysis and opsonophagocytosis. A second poster from Achillion, entitled “Comparison of complement functional assays: Differential sensitivities of hemolysis and Wieslab assays to levels of complement proteins C5, factor B, and factor D,” detailed the similarities and differences between inhibition of the alternative versus classical pathway in in vitro assays of complement activity.
“As we build upon our broad knowledge of the complement system, we continue to learn more about the unique role of the alternative pathway, its distinctions from the classical and lectin pathways, and its potential advantages in the treatment of rare diseases,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "With this important and exciting research, we continue to highlight the potential of factor D inhibition and look forward to advancing our first orally-administered small molecule, ACH-4471, into phase 2 clinical trials for both C3G and PNH during the fourth quarter of this year."
Reprints of the posters presented at the XXVIth International Complement Workshop will be available from the Resources section of the Achillion website at http://www.achillion.com.
About the Achillion Complement Factor D Platform
Achillion has leveraged its internal discovery capabilities and a novel complement-related platform to develop small molecule drug candidates that are oral inhibitors of complement factor D. Factor D is an essential serine protease involved in the complement pathway, a part of the innate immune system. Achillion's complement platform is focused on seeking to advance small molecule compounds that inhibit factor D and can potentially be used in the treatment of immune-related diseases in which complement alternative pathway plays a critical role. Potential indications being evaluated for these compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and dry age-related macular degeneration (dry AMD).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trovagene (TROV) Announces Publication of Study Results in Clinical Cancer Research
- Plug Power (PLUG) Says it Deployed 4,010 GenDrive Units in FY16, Exceeding Guidance
- Stonemor Partners (STON) Announces Resignation of CFO Sean McGrath
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!